Indian Generics Makers Reap Benefits Of U.S. FDA Push For Approvals
This article was originally published in PharmAsia News
Executive Summary
The decision by U.S. FDA to clear generic versions of Merck’s Singulair (montelukast) for treating asthma and allergies has been a boon to Indian drug makers such as Aurobindo and Glenmark.
You may also be interested in...
Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
COVID-19 Shows Remote Monitoring Can Work For Pre-Cert Program
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
Device Week, 18 September 2020 – Keeping The ‘Human’ In Human Factors Amidst COVID-19
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.
Need a specific report? 1000+ reports available
Buy Reports